Partnerships in Clinical Trials: Pharmaceutical and Managed Care AlliancesBarnett Educational ServicesFebruary 1, 1998 220 Pages - SKU: BNT1870245 |
| As the competitive landscape shifts, pharmaceutical companies have most recently turned to managed care organizations (MCOs) as a partner in conducting clinical trials. Partnering with MCOs provides pharmaceutical companies with the opportunity to focus on fewer, more effective pivotal trials, thereby reducing their cost and time-to-market. At the same time, these studies allow manufacturers to collect data in the environment in which they'll be marketing, hopefully paving the way to get their product on formulary. Many MCOs are wary of this new partnership, not convinced that the benefits outweigh the drawbacks of partnering with drug companies.
This is new territory for both MCOs and drug companies. Not surprisingly, there are many variables and issues to be resolved when approaching such a partnership from either side. Now there is a new publication, Partnerships in Clinical Trials: Pharmaceutical and Managed Care Alliances, that discusses the practical issues of such partnerships. This book is an approachable and usable reference for healthcare professionals who are involved in the design, implementation, or analysis of clinical and outcomes-based trials in managed-care settings. Industry experts from both sides of the partnership detail each step of the process, covering the benefits and the pitfalls of such trials. Organized in a logical, step-by-step format, with summaries and salient highlights, Partnerships in Clinical Trials: Pharmaceutical and Managed Care Alliances uses real-world case studies to illustrate how these projects benefit both organizations, including what to look out for, and how to proceed with each step of the trial. No other publication covers the "how-to" in such a practical and useful way. With Partnerships in Clinical Trials: Pharmaceutical and Managed Care Alliances, you'll learn about:
|
Related Markets
Research & Development Reports
- Outsourcing in Drug Discovery: The Contract Research Organization (CRO) Market, 5th Edition
- Oral Drug Delivery Market to 2017 - Out-licensing Proprietary Technologies for Proteins, Peptides and Small Molecules to Drive Revenue Growth
- Orphan Disease Therapeutics Market to 2018 - Improved Understanding of Rare Diseases' Heterogeneity and Novel New Clinical Trial Designs to Foster Innovation
- Cytotoxic Therapies Market to 2017 - Launch of Next Generation Camptothecin Analogues Will Help Offset Revenue Loss due to Generic Erosion
- Orphan Diseases Therapeutics in Oncology to 2018 - Strongly Diversified Developmental Pipelines Indicate Long-Term Growth Potential despite Moderate Scope of Current Late Stage Molecules
